IntegriChain has acquired the life sciences division of Cumberland

Lincoln International served as the exclusive financial advisor and debt arranger to IntegriChain on the acquisition, providing industry expertise, valuation and strategic guidance on the key investment thesis, proactively addressing lender concerns and generating multiple potential capital structure options, as well as offering advisory services and diligence support services.

Headquartered in Philadelphia, Pennsylvania, IntegriChain, Inc., a portfolio company of Accel-KKR, is a leading integrated platform of mission-critical, just-in-time proprietary data and analytics to pharma and life sciences manufacturers. IntegriChain’s solutions provide customers with custom tools and reports including inventory tracking, refined patient data, gross-to-net calculations and commercial and government payer management.

Founded in 2004, Cumberland is a leading healthcare consulting and services firm providing strategic advisory consulting services, technology services and outsourced managed services solutions to clients in the payer and provider markets.

Cumberland’s life sciences division, specifically, is a leading provider of managed services, advisory services and systems integration for contracts, pricing and revenue management. Cumberland’s life sciences division is headquartered in Edison, New Jersey, with additional operations in Raleigh, North Carolina.

Kevin Leininger, Co-founder and CEO of IntegriChain, commented, “This acquisition reinforces IntegriChain’s market-leading position to help manufacturers drive access and maximize their commercialization success throughout the brand life cycle, from pre-launch through growth. We now deliver the industry’s first and only data and managed services platform that unifies all of the critical business functions for commercialization and market access – contracts and pricing, gross-to-net, channel and patient services – unlocking strategic payer, provider and pharmacy insights for our customers. As a result of this transaction, we are uniquely positioned to address critical therapy access challenges and ensure patients have access to specialty and precision medicines. We welcome all Cumberland life science consultants and professionals to our expanding global team as we continue to partner with our extensive combined customer base of more than 220 life sciences manufacturers to solve their access challenges.”

Michael Siano, Managing Director at Lincoln International, commented, “We are delighted to have advised IntegriChain and AKKR on the acquisition of Cumberland’s life sciences division and to have arranged a flexible debt structure to facilitate the transaction. As life sciences manufacturers continue to integrate data and analytics into their workflows, we believe IntegriChain is very well-positioned to help address some of the pain points present in the industry today. This transformative acquisition broadens IntegriChain’s offering and significantly expands their customer base at a time when life sciences manufacturers are increasingly seeking vendors with complete offerings. We congratulate the team at AKKR and IntegriChain on the completion of this acquisition and we look forward to IntegriChain’s continued growth and success.”

  • 2020
    Close Year
  • Healthcare
  • PE Backed
    Client Type
  • Strategic | Domestic
    Transaction Type
  • USA
Lincoln’s considerable industry knowledge, strong understanding of our business model and insight into the trends in the HCIT market contributed significantly to the successful execution of this transaction.
Kevin Leininger
Co-Founder & CEO of IntegriChain

Meet our Senior Team